## AZN: Astrazeneca PLC - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.03 indicates fundamental undervaluation. Quality metrics strong (ROE 22%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($86.79)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 6, Bearish: 1)

**1. Rexford Capital Inc. Invests $948,000 in AstraZeneca PLC $AZN**
- Source: MarketBeat | 20251214T111016 | Bullish | Relevance: 100%
- Rexford Capital Inc. initiated a new position in AstraZeneca PLC (NASDAQ:AZN) during the second quarter, purchasing 13,566 shares valued at approximately $948,000. Several other institutional investors also significantly increased their holdings in AstraZeneca. The company recently exceeded quarterly earnings expectations and holds a "Moderate Buy" consensus analyst rating with a target price of $95.75.

**2. Why is AstraZeneca PLC (AZN) One of the Best Pharma Stocks to Invest In?**
- Source: Insider Monkey | 20251210T112800 | Bullish | Relevance: 100%
- AstraZeneca PLC (NASDAQ: AZN) is highlighted as a top pharma stock, with JPMorgan recently raising its price target to 16,000 GBP. The company received FDA acceptance for its New Drug Application (NDA) for baxdrostat, a potential first-in-class treatment for hard-to-control hypertension with a PDUFA date in Q2 2026. This development, based on positive Phase III trial data, underscores AstraZeneca's strong pipeline and growth prospects in the biopharmaceutical sector.

**3. Holocene Advisors LP Sells 124,752 Shares of AstraZeneca PLC $AZN**
- Source: MarketBeat | 20251214T131016 | Somewhat-Bullish | Relevance: 100%
- Holocene Advisors LP has reduced its stake in AstraZeneca PLC by selling 124,752 shares, bringing its total holdings to 4,321,629 shares valued at approximately $302 million. This move makes AstraZeneca the 26th-largest holding in the fund's portfolio, representing about 0.7% of its total assets. The company recently exceeded quarterly expectations with an EPS of $1.19 and revenue of $15.19 billion, while analysts currently rate AZN as a "Moderate Buy" with a target price of $95.75.

**4. AstraZeneca PLC $AZN Shares Bought by Cubist Systematic Strategies LLC**
- Source: MarketBeat | 20251213T111038 | Bullish | Relevance: 100%
- Cubist Systematic Strategies LLC significantly increased its stake in AstraZeneca PLC, purchasing an additional 249,364 shares in the second quarter, bringing its total holdings to 484,078 shares valued at $33.83 million. Other institutional investors also modified their positions in AZN. The pharmaceutical giant recently exceeded Q3 earnings estimates with EPS of $1.19 and revenue of $15.19 billion, and analysts currently rate the stock as a "Moderate Buy" with a consensus target price of $95.75.

**5. AstraZeneca (AZN) At the Center of Serious Analyst Attention**
- Source: Insider Monkey | 20251212T073300 | Bullish | Relevance: 100%
- AstraZeneca PLC (NASDAQ:AZN) has garnered significant analyst attention recently, with TD Cowen, Morgan Stanley, and Bank of America all raising their price targets for the pharmaceutical giant. Analysts are optimistic due to AstraZeneca's robust drug pipeline and presence in high-growth markets, despite some suggesting that investors seeking pure growth might look to other sectors. Bank of America even added AZN to its top stocks for 2026 list, highlighting drugs like SERENA-4, Eplontersen, and AVANZAR.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 10.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Price (T.Rowe) Assoc: 1.9% (-5.4%)
- Primecap Management : 1.5% (-3.3%)
- Bank of America Corp: 1.2% (+4.7%)
- Wellington Managemen: 1.2% (-5.9%)
- Capital Internationa: 0.9% (-20.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Quality metrics strong (ROE 22%, margin 16%). Balance sheet: $4.4B free cash flow. Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $278.5B |
| Beta | 0.17 |
| 52W Range | $61.24 - $94.02 |
| Short Interest | 0.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 17.4 |
| Current P/E | 19.6 |
| YoY Growth | 12.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -1.2% (minimal 5-day change). Below STRENGTH zone by 5.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.6%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). RSI neutral at 53. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.24% (CS: 28) | Neutral |
| RSI_14 | 52.8 | Neutral |
| MACD Histogram | -0.40 | Bearish |
| vs SMA20 | 0.992x | Below |
| vs SMA50 | 1.034x | Above |
| vs SMA200 | 1.169x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $89.83
- **Stop Loss:** $86.79 (3.4% risk)
- **Target:** $95.91 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 328
- **Position Value:** $29,464.24
- **Portfolio %:** 29.46%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-10 (Est: $1.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.13 | $1.19 | +4.9% |
| 2025Q2 | $1.46 | $1.08 | -25.9% |
| 2025Q1 | $1.12 | $1.25 | +11.6% |
| 2024Q4 | $1.04 | $1.04 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*